Ineffective treatment no more

We developed a set of specialized assets for precision oncology.

check out Our assets

MNM177

MNM177 is a novel drug target linked to DNA damage response and replication stress pathways. Inhibition of MNM177 in tumors with genomic instability leads to the death of cancer cells. The MNM177 was discovered in thousands of real patients’ data via our ARETEAI platform.

The platform by analysis of data from tumor genomes has identified patterns indicative of the molecular pathway the replication-stress high tumors are addicted to. MNM177 is the first-in-class drug target identified using such deconvoluting approach. The MNM177 inhibitor has the potential for both combination therapy and monotherapy (as a single agent could even surpass PARP inhibitors due to its essential role in MMEJ).

Target
Discovery
Lead
Identification
IND Enabling
Phase I
- Clinical trials
MNM177
MNM391
MNM825

MNM177 first indication: breast.

MNM177 can be used in replication stress-high tumors.

Most tumors have an elevated level of replication stress, so it gives MNM177, a broad therapeutic indications.

ARETEAI

PATHWAY DECONVOLUTION FROM GENOMIC PATTERNS, AI-driven drug target platform

Drug target
discovery
Predictive
algorithms
Identify tumor addiction and cohort selection

In Vitro & In Vivo Research Laboratory

Drug target candidates are extensively validated in our Research Laboratory.

  • Bioanalytical and cell-based assays
  • X-ray crystallography
  • Cell cultures and animal models
  • Pre-clinical research

Predictive algorithms for precision medicine

We also develop predictive algorithms that stratify oncological patients for targeted therapies. These algorithms predict drug response based on tumor molecular patterns.

Our AI-discovered algorithms for therapy response prediction

Cancer no more

Our proprietary platform applies AI to tumor's dark genome to personalize therapy for every cancer patient.

Our technology